Latest revenue
$699.1K
as of 2025-12-31
Latest net income
$-28.9M
as of 2025-12-31
Net margin
-4127.6%
as of 2025-12-31
ActaClear Score
Computed from 5 years of SEC fundamentals + latest market data, ranked within Pharmaceutical Preparations (528 peers). 10 = best in industry, 5 = median, 0 = worst. Refreshed Jun 7, 2026.
Community sentiment
Where do you think ANVS is heading?
Price · 5Y
Live market
delayed ≤15 min- Market cap
- $65.1M
- Enterprise value
- $51.4M
- P/E (trailing)
- —
- Forward P/E
- —
- P/B
- 20.84×
- Dividend yield
- 0.0%
- 52-wk high
- $5.50
- 52-wk low
- $1.54
- Beta
- —
- Shares out
- 34.6M
5-year trend
What this company does
Item 1. Business. Our Company We are a late-stage clinical drug platform company addressing neurodegeneration, such as Alzheimer’s disease (“AD”) and Parkinson’s disease (“PD”). We are developing our lead product candidate, buntanetap, which is designed to address AD, PD, and potentially other chronic neurodegenerative diseases. Buntanetap is a synthetically produced small molecule, orally administered, brain penetrant compound. In several studies, buntanetap was observed to inhibit the synthesis of neurotoxic proteins — APP/Aβ (“APP”), tau/phospho-tau (“tau”), α-Synuclein (“αSYN”) and TDP43 — that are some of the main causes of neurodegeneration. High levels of neurotoxic proteins lead to…
AI summary unavailable — showing raw filing excerpt
Generated from ANVS's filing dated 2026-03-13
Key risks
Item 1A. Risk Factors Risks Related to Our Financial Position and Need for Additional Capital We have incurred losses since inception and anticipate that we will continue to incur losses for the foreseeable future. We are not currently profitable, and we may never achieve or sustain profitability. We are a clinical stage biopharmaceutical company with a limited operating history and have incurred losses since our formation. We incurred net losses of $990,980 and $713,871 for the years ended December 31, 2019 and 2018, respectively. As of December 31, 2019, we had an accumulated deficit of $8,777,028. We have not commercialized any products and have never generated revenue from the…
AI summary unavailable — showing raw filing excerpt
Generated from ANVS's filing dated 2026-03-13
Profitability
Operating margin
-4247.9%
47.2%Net margin
-4127.6%
44.3%Return on equity
-171.2%
154.0%Return on assets
-136.9%
22.5%Leverage
Debt / equity
0.25×
109.0%Debt / assets
20.1%
87.1%Earnings tracker
| Quarter | Revenue | YoY | Net income | YoY | Net margin |
|---|---|---|---|---|---|
Q1 2026 2026-03-31 | — | — | $-17.6M | -218.0% | — |
Q4 2025 2025-12-31 | — | — | $-9.8M | -67.7% | — |
Q3 2025 2025-09-30 | — | — | $-7.3M | +42.5% | — |
Q2 2025 2025-06-30 | — | — | $-6.2M | -23.9% | — |
Q1 2025 2025-03-31 | — | — | $-5.5M | -419.0% | — |
Q4 2024 2024-12-31 | — | — | $-5.9M | — | — |
Q3 2024 2024-09-30 | — | — | $-12.6M | +14.1% | — |
Q2 2024 2024-06-30 | — | — | $-5.0M | +47.4% | — |
Year-over-year change vs the same fiscal quarter one year prior. Revenue + net income sourced from SEC 10-Q / 10-K filings — no analyst-consensus dependency.
Industry trend
Pharmaceutical Preparations · SIC 2834
Your notes
Keep private notes on ANVS — thesis, target price, catalysts to watch.
Visible only to you. Never shared. Never used to train AI.
Insider activity
Insider buying
$4.5M
Insider selling
$0
Net activity
+$4.5M
Distinct insiders
2
Open-market trades over the last 365 days.
Recent transactions
Source: SEC Form 4 filings. Officers, directors, and 10%+ owners must disclose share transactions within two business days. RSU grants and tax-withholding rows are excluded by default — compensation activity is not a trading signal.
Who owns ANVS
Institutional value
$3.8M
Total shares held
1.8M
Distinct holders
39
-14 vs prior
As of
2026-03-31
Prior: 2025-12-31
Filers with $100M+ AUM disclose holdings 45 days after quarter end.
Top institutional holders
| # | Manager | Shares | Value | QoQ change | Action |
|---|---|---|---|---|---|
| 1 | VANGUARD CAPITAL MANAGEMENT LLC | 872.4K | $1.9M | — | New |
| 2 | BlackRock, Inc. | 139.5K | $311.2K | +0 (+0.0%) | No change |
| 3 | VANGUARD FIDUCIARY TRUST CO | 132.0K | $294.5K | — | New |
| 4 | Merit Financial Group, LLC | 81.3K | $181.3K | +0 (+0.0%) | No change |
| 5 | GROUP ONE TRADING LLC | 69.7K | $155.3K | +537 (+0.8%) | Added |
| 6 | Sherry Group, Inc. | 57.3K | $127.7K | +30.0K (+110.0%) | Added |
| 7 | Wescott Financial Advisory Group, LLC | 41.6K | $92.8K | +0 (+0.0%) | No change |
| 8 | First National Trust Co | 40.0K | $89.2K | +0 (+0.0%) | No change |
| 9 | Dakota Wealth Management | 26.0K | $58.0K | -200 (-0.8%) | Trimmed |
| 10 | Sterling Investment Advisors, Ltd. | 23.4K | $52.2K | +0 (+0.0%) | No change |
| 11 | UBS Group AG | 21.5K | $48.0K | -9.1K (-29.7%) | Trimmed |
| 12 | Wealthspire Advisors, LLC | 20.0K | $44.6K | +0 (+0.0%) | No change |
| 13 | Robertson Stephens Wealth Management, LLC | 18.6K | $41.4K | +0 (+0.0%) | No change |
| 14 | GILL CAPITAL PARTNERS, LLC | 18.6K | $41.4K | +0 (+0.0%) | No change |
| 15 | CWA Asset Management Group, LLC | 17.0K | $37.9K | +0 (+0.0%) | No change |
| 16 | Bank of New York Mellon Corp | 15.5K | $34.5K | -4.6K (-22.8%) | Trimmed |
| 17 | Koshinski Asset Management, Inc. | 15.0K | $33.5K | +18 (+0.1%) | Added |
| 18 | WELLS FARGO & COMPANY/MN | 14.3K | $31.9K | +0 (+0.0%) | No change |
| 19 | JPMORGAN CHASE & CO | 14.9K | $29.9K | +0 (+0.0%) | No change |
| 20 | Vanguard Global Advisers, LLC | 11.2K | $25.0K | — | New |
Source: SEC Form 13F-HR. Positions aggregated across sub-managers within each firm. Options (puts/calls) excluded — common stock only.
Top questions investors are asking
Coming once ANVS's latest filing finishes processing.
Sign in to vote. Votes use 7-day half-life decay.
Sign in to tap. 7-day half-life decay.